Nuveen Select Tax-Free Income Portfolio (NXP)

Nuvectis Stock Surges Around 97% in 3 Months: Here's Why

NXP Semiconductors Sees Demand Rebound as Auto, AI and Data Center Growth Accelerate

NXP Semiconductors Breaks Ground on Assembly and Test Site Expansion in Malaysia

This Wall Street Pro Makes a Compelling Argument for 70% Gains on NXP Semiconductors Which Cratered Last Month

Why NXP Semiconductors Stock Dropped 18.5% in July

NXP Trimension Ultra-Wideband Powers BMW Group's Digital Key Plus and Presence Detection

NXP downgraded by UBS as China and AI risks cloud growth

NXP in talks to buy chip developer Ambarella, FT reports

NXP Semiconductors Q2 Earnings Beat Estimates, Revenues Rise Y/Y

NXP Semiconductor: A Solid Q2, And Improved Q3 Guidance Reiterates The Bull Case

NXP Semiconductors Q2 Earnings Call Highlights

NXP Semiconductors Shares Slip Despite Q2 Earnings Beat

NXP Semiconductors Second-Quarter Profit, Revenue Climb on Growth Across End Markets

NXP Semiconductors Reports Second Quarter 2026 Results

For Energy Investors, Is a Traditional Energy ETF a Better Bet Than Clean Energy?

Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

NXP Semiconductors: Why I Think The Valuation Discount Is Too Harsh

NXP Semiconductors Announces Conference Call to Review Second Quarter 2026 Financial Results